Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 147 results for sclerosis

  1. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...

    Research recommendation
    Published
    9 June 2015

  2. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

    Medtech innovation briefing
    Published
    26 July 2016

  3. Self-expanding implant insertion into the intersphincteric space for faecal incontinence (HTG564)

    Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.

    HealthTech guidance
    Published
    27 January 2021
    View recommendations

    Sections for HTG564

  4. Past appeals and decisions

    Past technology appraisal appeals and decisions

  5. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

    HealthTech guidance
    Published
    25 November 2015
    View recommendations

    Sections for HTG391

  6. Transabdominal artificial bowel sphincter implantation for faecal incontinence (HTG177)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

    HealthTech guidance
    Published
    26 November 2008
    View recommendations

    Sections for HTG177

  7. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    product in UK: Sativex) for treating spasticity in people with multiple sclerosis. There were reductions in some measures of...

    Research recommendation
    Published
    10 February 2020

  8. Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (HTG191)

    Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.

    HealthTech guidance
    Published
    27 May 2009
    View recommendations

    Sections for HTG191

  9. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  10. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

    Technology appraisal guidance
    Discontinued

  11. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    dysfunction, as well as those with spinal cord injury, spina bifida and multiple sclerosis. Reports of its use in other conditions are...

    Research recommendation
    Published
    9 June 2015

  12. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  13. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    function. In the population with neurological diseases such as multiple sclerosis, Parkinson's disease and dementia, the rise in...

    Research recommendation
    Published
    9 June 2015

  14. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  15. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued